Mixed data for J&J's antidepressant in Phase III trials

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported mixed data from two Phase III trials testing intranasal esketamine (formerly JNJ-54135419) in patients with treatment-resistant

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE